Skip to main content
Equibles
REGN logo

REGN · Regeneron Pharmaceuticals, Inc. · Metrics

Track REGN — free

Use REGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research REGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$955.47 +4.28 (+0.45%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
S&P 500 member Nasdaq-100 member Russell 1000 member Rebalance outlook locked
Market Cap
$98.84B
Shares
103.45M
Volume · Nov 13 1.17M Avg daily vol (3M) 792.82K

REGN metrics

113 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$955.47
Market cap
$98.84B

Price action

23 metrics
Price change (1W)
+5.7%
Price change (30D)
+20.0%
Price change (3M)
+18.9%
Price change (6M)
+36.8%
Price change (YTD)
+23.8%
Price change (1Y)
+37.5%
Trailing year
Price change (5Y)
+51.4%
52-week high
$973.36
52-week low
$600.66
Change from 52-week high
-1.8%
Change from 52-week low
+59.1%
Annualized volatility
34.1%
Annualized volatility (3M)
39.8%
Implied volatility (30D)
33.5%
IV rank (1Y)
42.1
IV percentile (1Y)
39.4
Beta
0.4
RSI (14D)
68.4
Price vs SMA 50
+17.1%
Price vs SMA 200
+27.9%
Avg volume (3M)
792,816
Relative volume
1.5
Average dollar volume
$660.63M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
103.45M

Valuation

12 metrics
P / E (TTM)
21.1
Trailing earnings · reciprocal yield 4.7%
PEG ratio
0.6
EV / revenue
5.5×
reciprocal yield 18.3%
EV / EBITDA
17.2×
reciprocal yield 5.8%
EV / EBIT
19.0×
reciprocal yield 5.3%
P / sales
5.8×
reciprocal yield 17.1%
P / book
3.0
reciprocal yield 33.9%
FCF yield
3.9%
TTM · current market cap
Buyback yield
3.1%
P / FCF
25.8
reciprocal yield 3.9%
P / operating cash flow
20.4
reciprocal yield 4.9%
Earnings yield
4.9%

Historical valuation

8 metrics
P / E historical average (3Y)
20.4×
reciprocal yield 4.9%
P / E historical average (5Y)
18.2×
reciprocal yield 5.5%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
0.4%
Trailing 12 months
Payout ratio
8.0%
Shareholder yield
3.5%
Dividend / share (TTM)
$3.70
Dividend growth YoY
+40.2%
Dividend growth streak
—
Last ex-dividend
2026-08-18

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-30

Profitability

9 metrics
Gross margin
—
Operating margin
28.8%
Trailing 12 months
Net margin
28.5%
Gross profit (TTM)
$5.85B
Operating profit (TTM)
$4.86B
Net income (TTM)
$4.82B
Trailing 12 months
Diluted EPS (TTM)
$45.21
FCF margin
22.6%
Effective tax rate
15.3%

Per share

11 metrics
Revenue per diluted share (TTM)
$158.55
Gross profit per diluted share (TTM)
$50.54
Operating profit per diluted share (TTM)
$45.76
EBITDA per diluted share (TTM)
$50.56
Net income per diluted share (TTM)
$45.30
Operating cash flow per diluted share (TTM)
$45.47
Free cash flow per diluted share (TTM)
$35.91
Capital expenditures per diluted share (TTM)
$9.56
R&D per diluted share (TTM)
$61.85
Stock compensation per diluted share (TTM)
$9.42
Book value per share
$8.54

Growth

11 metrics
Revenue growth YoY
+36.3%
Year over year
Net income growth YoY
+33.5%
Revenue (TTM)
$16.90B
Trailing 12 months
EPS growth YoY
+35.5%
Shares change YoY
-1.5%
Year over year · fewer shares
Revenue CAGR (3Y)
+5.6%
Revenue CAGR (5Y)
+11.0%
EPS CAGR (3Y)
+2.8%
EPS CAGR (5Y)
+6.3%
FCF CAGR (3Y)
-2.7%
FCF CAGR (5Y)
+15.3%

Quality

14 metrics
Return on equity
14.4%
Return on assets
10.8%
Debt / equity
0.1
Current ratio
3.4
EBITDA (TTM)
$5.38B
Free cash flow (TTM)
$3.83B
Quick ratio
2.9
Interest coverage
104.2
Net debt / EBITDA
-1.2
Return on invested capital
15.3%
Trailing 12 months
Net cash
$6.59B
Latest balance sheet
Cash & equivalents
$3.66B
Total assets
$44.41B
Total debt
$2.71B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$4.85B
Capital expenditures (TTM)
$1.02B
R&D (TTM)
$6.60B
SG&A (TTM)
$2.76B
Stock compensation (TTM)
$1.01B
R&D / revenue
39.0%
Stock compensation / revenue
6.0%

Ownership (13F)

9 metrics
13F filers
1,345
13F filer change QoQ
-60
Institutional ownership
91.1%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+2.3%
Holder tenure
18.5
Price vs estimated holder cost
-5.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
20.1%

Short interest

3 metrics
Short interest
2.1%
Latest settlement · 2.7 days to cover
Days to cover
2.7d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$51.90M
Insider-sentiment score
10 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 872589 CUSIP 75886F107 13F (30d) 1142 filings 1071 filers Visit website Investor relations